Comparison of characteristics and ventilatory course between coronavirus disease 2019 and Middle East respiratory syndrome patients with acute respiratory distress syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Both coronavirus disease 2019 (COVID-19) and Middle East respiratory syndrome (MERS) can cause acute respiratory distress syndrome (ARDS); however, their ARDS course and characteristics have not been compared, which we evaluate in our study. Methods: MERS patients with ARDS seen during the 2014 outbreak and COVID-19 patients with ARDS admitted between March and December 2020 in our hospital were included, and their clinical characteristics, ventilatory course, and outcomes were compared. Results: Forty-nine and 14 patients met the inclusion criteria for ARDS in the COVID-19 and MERS groups, respectively. Both groups had a median of four comorbidities with high Charlson comorbidity index value of 5 points (P>0.22). COVID-19 patients were older, obese, had significantly higher initial C-reactive protein (CRP), more likely to get trial of high-flow oxygen, and had delayed intubation (P≤0.04). The postintubation course was similar between the groups. Patients in both groups experienced a prolonged duration of mechanical ventilation, and majority received paralytics, dialysis, and vasopressor agents (P>0.28). The respiratory and ventilatory parameters after intubation (including tidal volume, fraction of inspired oxygen, peak and plateau pressures) and their progression over 3 weeks were similar (P>0.05). Rates of mortality in the ICU (53% vs. 64%) and hospital (59% vs. 64%) among COVID-19 and MERS patients (P≥0.54) were very high. Conclusions: Despite some distinctive differences between COVID-19 and MERS patients prior to intubation, the respiratory and ventilatory parameters postintubation were not different. The higher initial CRP level in COVID-19 patients may explain the steroid responsiveness in this population.
Abstract
Background: Both coronavirus disease 2019 (COVID-19) and Middle East respiratory syndrome (MERS) can cause acute respiratory distress syndrome (ARDS); however, their ARDS course and characteristics have not been compared, which we evaluate in our study. Methods: MERS patients with ARDS seen during the 2014 outbreak and COVID-19 patients with ARDS admitted between March and December 2020 in our hospital were included, and their clinical characteristics, ventilatory course, and outcomes were compared. Results: Forty-nine and 14 patients met the inclusion criteria for ARDS in the COVID-19 and MERS groups, respectively. Both groups had a median of four comorbidities with high Charlson comorbidity index value of 5 points (P>0.22). COVID-19 patients were older, obese, had significantly higher initial C-reactive protein (CRP), more likely to get trial of high-flow oxygen, and had delayed intubation (P≤0.04). The postintubation course was similar between the groups. Patients in both groups experienced a prolonged duration of mechanical ventilation, and majority received paralytics, dialysis, and vasopressor agents (P>0.28). The respiratory and ventilatory parameters after intubation (including tidal volume, fraction of inspired oxygen, peak and plateau pressures) and their progression over 3 weeks were similar (P>0.05). Rates of mortality in the ICU (53% vs. 64%) and hospital (59% vs. 64%) among COVID-19 and MERS patients (P≥0.54) were very high. Conclusions: Despite some distinctive differences between COVID-19 and MERS patients prior to intubation, the respiratory and ventilatory parameters postintubation were not different. The higher initial CRP level in COVID-19 patients may explain the steroid responsiveness in this population.
참고문헌 (28)
- Shaver CM, "Clinical and biological heterogeneity in acute respiratory distress syndrome : direct versus indirect lung injury", Clin Chest Med, 35, pp.639~653 (2014)
- Gralinski LE, "Molecular pathology of emerging coronavirus infections", J Pathol, 235, pp.185~195 (2015)
- Wong CK, "Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome", Clin Exp Immunol, 136, pp.95~103 (2004)
- Cockrell AS, "A mouse model for MERS coronavirus-induced acute respiratory distress syndrome", Nat Microbiol, 2, pp.16226~ (2016)
- Lew TW, "Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome", JAMA, 290, pp.374~380 (2003)
- Khalid I, "Acute management and long-term survival among subjects with severe Middle East respiratory syndrome coronavirus pneumonia and ARDS", Respir Care, 61, pp.340~348 (2016)
- Li X, "Acute respiratory failure in COVID-19: is it “typical”ARDS?", Crit Care, 24, pp.198~ (2020)
- COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, "Clinical characteristics and day-90outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study", Intensive Care Med, 47, pp.60~73 (2021)
- Panadero C, "Highflow nasal cannula for acute respiratory distress syndrome(ARDS)due to COVID-19", Multidiscip Respir Med, 15, pp.693~ (2020)
- Gibson PG, "COVID-19 acute respiratory distress syndrome(ARDS) : clinical features and differences from typical pre-COVID-19 ARDS", Med J Aust, 213, pp.54~56 (2020)
- REMAP-CAP Investigators, "Interleukin-6 receptor antagonists in critically ill patients with Covid-19", N Engl J Med, 384, pp.1491~1502 (2021)
- Arabi YM, "Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome", Am J Respir Crit Care Med, 197, pp.757~767 (2018)
- Stockman LJ, "SARS: systematic review of treatment effects", PLoS Med, 3, pp.e34~ (2006)
- ARDS Definition Task Force, "Acute respiratory distress syndrome: the Berlin Definition", JAMA, 307, pp.2526~2533 (2012)
- Zumla A, "Middle East respiratory syndrome", Lancet, 386, pp.995~1007 (2015)
- 김은영, "Identification of risk factors for mortality in COVID-19 patients", Acute and Critical Care, 35(4), pp.296~297 (2020), 대한중환자의학회[DOI]
- Pais FM, "Influence of clinical factors and exclusion criteria on mortality in ARDS observational studies and randomized controlled trials", Respir Care, 63, pp.1060~1069 (2018)
- Lyons PG, "Factors associated with clinical deterioration among patients hospitalized on the wards at a tertiary cancer hospital", J Oncol Pract, 15, pp.e652~e665 (2019)
- Frat JP, "High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure", N Engl J Med, 372, pp.2185~2196 (2015)
- Mellado-Artigas R, "High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure", Crit Care, 25, pp.58~ (2021)
- Avinash Kumar Jha, "Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom", Acute and Critical Care, 36(1), pp.1~14 (2021), 대한중환자의학회[DOI]
- Lal Tusharindra, "COVID-19 patients: when and whom to ventilate?", Acute and Critical Care, 35(3), pp.218~219 (2020), 대한중환자의학회[DOI]
- Fajgenbaum DC, "Cytokine storm", N Engl J Med, 383, pp.2255~2273 (2020)
- Burnham EL, "Detection of fibroproliferation by chest high-resolution CT scan in resolving ARDS", Chest, 146, pp.1196~1204 (2014)
- John S. Zorbas, "Airway pressure release ventilation in mechanically ventilated patients with COVID-19: a multicenter observational study", Acute and Critical Care, 36(2), pp.143~150 (2021), 대한중환자의학회[DOI]
- Meduri GU, "Prolonged glucocorticoid treatment is associated with improved ARDS outcomes : analysis of individual patients’data from four randomized trials and trial-level meta-analysis of the updated literature", Intensive Care Med, 42, pp.829~840 (2016)
- Ayaz Ahmed, "Risk factors for intensive care unit admission and mortality in hospitalized COVID-19 patients", Acute and Critical Care, 35(4), pp.249~254 (2020), 대한중환자의학회[DOI]
- Fadel Francois Abi, "Clinical characteristics and outcomes of critically Ill patients with COVID-19 in Northeast Ohio: low mortality and length of stay", Acute and Critical Care, 35(4), pp.242~248 (2020), 대한중환자의학회[DOI]